RxDoctor Payments Data

Sierra Cash

Primary Care · Edina, MNNPI 1467165407

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Medtronic at 47.7% of the total.

$1,036in general payments, 2019–2025

Across 34 payments — averaging $30.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$494
  • Saluda Medical Americas, Inc.$111
  • Spinal Simplicity, LLC$96
  • Abbott$74
  • Nevro Corp.$67
  • Collegium Pharmaceutical, Inc.$62
  • plus $131 from 5 others

What the payments were for

  • Food & beverage$1,036100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,036 in reported general payments places this provider in the 85th percentile of 54 primary care providers in Minnesota.

See all primary care providers in Minnesota

Medicare billing

Part B allowed, 2024
$133,692
Medicare patients
250
Services billed
888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl129$103,207
Buprenorphine130$34,033
QuliptaAtogepant12$15,220
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen446$8,564
Oxycodone Hcl537$7,050
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen324$6,535
Gabapentin305$6,033
Pregabalin232$4,101
OxycontinOxycodone Hcl18$3,856
Tizanidine Hcl235$3,531
Cyclobenzaprine Hcl191$2,628
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$2,375
Buprenorphine Hcl85$2,338
Methocarbamol130$1,842
Hydromorphone Hcl113$1,770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$62$103,207129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 54 primary care providers in Minnesota.

Other primary care in Edina

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →